ASCENDIS PHARMA A/S (ASND:NASDAQ)
$229.23 6.54 (2.9368%)
Analysed ASCENDIS PHARMA A/S (ASND:NASDAQ) News Sources
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
10-09-2026
yahoo.com
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
12-09-2026
yahoo.com
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
14-09-2026
yahoo.com
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback
15-09-2026
yahoo.com
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
15-09-2026
yahoo.com
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says
16-09-2026
yahoo.com
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
17-09-2026
yahoo.com
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs
19-09-2026
yahoo.com
Ascendis Pharma (ASND) Authorizes $400M Share Buyback
21-09-2026
yahoo.com
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
06-10-2026
yahoo.com
What is the current price of ASCENDIS PHARMA A/S (ASND:NASDAQ)?
The current price of ASCENDIS PHARMA A/S (ASND:NASDAQ) is $229.23.
ASCENDIS PHARMA A/S (ASND:NASDAQ) absolute price change since previous trading day?
The absolute price change of ASCENDIS PHARMA A/S (ASND:NASDAQ) since the previous trading day is $6.54.
ASCENDIS PHARMA A/S (ASND:NASDAQ) percentage price change since previous trading day?
The percentage price change of ASCENDIS PHARMA A/S (ASND:NASDAQ) since the previous trading day is 2.9368%.
What is the most recent average sentiment score for ASCENDIS PHARMA A/S (ASND:NASDAQ)?
The most recent average sentiment score for ASCENDIS PHARMA A/S (ASND:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for ASCENDIS PHARMA A/S (ASND:NASDAQ)?
The most recent sentiment for ASCENDIS PHARMA A/S (ASND:NASDAQ) is .
SEC-8K** Filing Available For ASCENDIS PHARMA A/S (ASND:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.